Participated · Series B · Aug 2026

Inocras develops whole-genome sequencing and proprietary bioinformatics solutions to translate comprehensive genomic data into curated, clinically actionable insights. Its oncology offerings include CancerVision™ for comprehensive tumor profiling and MRDVision™ for molecular residual disease detection, with automated interpretation capabilities. The company operates a CLIA/CAP-certified laboratory and reports real-world clinical adoption across Asia, with its solutions used by more than 100 cancer institutions and in thousands of patient cases. Inocras has established a significant commercial presence in Hong Kong and supports approximately thirty hospitals in South Korea. The company has collaborated with researchers at the Broad Institute to analyze whole-genome data from The Cancer Genome Atlas, informing broader use of standardized whole-genome analysis. The recent fundraise brought total funding to approximately $100 million to support further commercial expansion, particularly into the United States.

Participated · Series A · Jul 2026

Flexell Space develops next-generation space solar solutions and announced a $20 million Series A on July 14. The company is identified in the press release as being based in Uiwang, South Korea. Public reporting about the round does not include specifics on product roadmaps, customers, revenues, or other operating metrics. The articles also do not disclose how the company plans to deploy the new capital. No information about prior funding rounds or valuation was provided in the cited coverage.

Participated · Series C · Apr 2026

Founded in 2020 and headquartered in South Korea, Upstage builds large language models (including its SOLAR LLM) and a document processing solution called Document PATH. Its product suite focuses on converting unstructured data into actionable insights through document parsing and information extraction to automate enterprise workflows. The company targets industries such as insurance, healthcare, and finance. Following the Series C, Upstage achieved a valuation above 1 trillion won and plans to expand GPU infrastructure and hire global AI talent. It also intends to scale operations internationally, particularly across the U.S. and Japan. The article did not disclose revenue, user counts, or other operating metrics.

Participated · Series B · Mar 2026

Vitestro is a Netherlands-headquartered medical-robotics company focused on automating diagnostic blood draws with its Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™). The CE-marked system combines multimodal imaging, advanced robotics, and artificial intelligence to locate veins, guide needle insertion, and collect blood with high precision and consistency. By standardizing venous access, the platform aims to alleviate staffing shortages, reduce variability, and improve patient experience in high-volume outpatient environments. Vitestro is currently deploying Aletta® in clinical and pre-commercial sites across Europe while pursuing a U.S. FDA De Novo clearance. Proceeds from its latest financing will fund next-generation product development, manufacturing scale-up, additional clinical studies, and the build-out of global commercial infrastructure.

Participated · Series B · Feb 2026

Galux leverages its proprietary GaluxDesign platform, which integrates deep-learning with biophysical principles, to design high-affinity antibodies and other proteins from scratch. The platform has already produced antibodies whose AI-predicted structures align closely with cryo-EM data, validating its precision and generalizability. Galux is expanding the technology to harder target classes such as GPCRs and ion channels while tightly coupling AI modeling with wet-lab feedback to speed iteration. The company has formed co-development partnerships with Celltrion, LG Chem, and most recently Boehringer Ingelheim to broaden its pipeline and global reach. Proceeds from the latest financing will enhance the AI engine, grow R&D infrastructure, and advance proprietary programs into preclinical validation. Since its 2022 $18 million Series A, Galux has hit multiple R&D and business milestones, helping it secure the follow-on funding. Cumulatively, the company has raised $47 million to date.